[go: up one dir, main page]

MX2020010942A - Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales. - Google Patents

Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.

Info

Publication number
MX2020010942A
MX2020010942A MX2020010942A MX2020010942A MX2020010942A MX 2020010942 A MX2020010942 A MX 2020010942A MX 2020010942 A MX2020010942 A MX 2020010942A MX 2020010942 A MX2020010942 A MX 2020010942A MX 2020010942 A MX2020010942 A MX 2020010942A
Authority
MX
Mexico
Prior art keywords
inhibitors
dna
tumor therapy
dual atm
atm
Prior art date
Application number
MX2020010942A
Other languages
English (en)
Inventor
Jianmin Fu
Guosheng Wu
Aijun Lu
Yaode Wang
Yue Sun
Shuang Zhang
Robert Goodnow
Tona Gilmer
Michael Kastan
David Kirsch
Original Assignee
Xrad Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xrad Therapeutics Inc filed Critical Xrad Therapeutics Inc
Priority claimed from PCT/CN2019/083104 external-priority patent/WO2019201283A1/en
Publication of MX2020010942A publication Critical patent/MX2020010942A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporcionan en la presente compuestos de las Fórmulas (I), (II) y (III), así como sales farmacéuticamente aceptables de estos, donde los sustituyentes son aquellos descritos en la memoria descriptiva. Estos compuestos, y las composiciones farmacéuticas que los contienen, son útiles para el tratamiento de enfermedades oncológicas.
MX2020010942A 2018-04-20 2019-04-17 Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales. MX2020010942A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810359447.6A CN110386932A (zh) 2018-04-20 2018-04-20 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
US201862665296P 2018-05-01 2018-05-01
PCT/CN2019/083104 WO2019201283A1 (en) 2018-04-20 2019-04-17 Dual atm and dna-pk inhibitors for use in anti-tumor therapy

Publications (1)

Publication Number Publication Date
MX2020010942A true MX2020010942A (es) 2021-01-15

Family

ID=68283636

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020010942A MX2020010942A (es) 2018-04-20 2019-04-17 Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.

Country Status (10)

Country Link
US (1) US12187742B2 (es)
EP (2) EP3784671B1 (es)
JP (1) JP7366996B2 (es)
KR (1) KR20210027251A (es)
CN (2) CN110386932A (es)
BR (1) BR112020021323A2 (es)
CA (1) CA3096732A1 (es)
MA (1) MA52364A (es)
MX (1) MX2020010942A (es)
SG (1) SG11202010212RA (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10118890B2 (en) 2014-10-10 2018-11-06 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
WO2019201283A1 (en) 2018-04-20 2019-10-24 Xrad Therapeutics, Inc. Dual atm and dna-pk inhibitors for use in anti-tumor therapy
EP4003345B1 (en) * 2019-07-30 2024-12-04 XRad Therapeutics, Inc. Dual atm and dna-pk inhibitors for use in anti-tumor therapy
WO2021098734A1 (zh) * 2019-11-19 2021-05-27 南京明德新药研发有限公司 作为atm抑制剂的有取代的喹啉吡咯酮类合物及其应用
AU2020385513A1 (en) * 2019-11-22 2022-07-14 Medshine Discovery Inc. Pyrimidopyrrole spiro compounds and derivatives thereof as DNA-PK inhibitors
WO2021136462A1 (zh) * 2019-12-31 2021-07-08 成都百裕制药股份有限公司 呋喃衍生物及其在医药上的应用
CN115380031A (zh) * 2020-03-30 2022-11-22 南京明德新药研发有限公司 作为atm抑制剂的喹啉并吡咯烷-2-酮类化合物的晶型及其应用
CN114634521A (zh) * 2020-12-15 2022-06-17 首药控股(北京)股份有限公司 Dna-pk选择性抑制剂及其制备方法和用途
CN121152622A (zh) * 2023-03-06 2025-12-16 艾科思莱德控股开曼有限公司 治疗癌症的方法
WO2025247391A1 (en) * 2024-05-31 2025-12-04 Hutchmed Limited Novel pi3k and/or pikk inhibitors, antibody-drug conjugates comprising the same and uses thereof
WO2026006954A1 (en) * 2024-07-01 2026-01-08 Xrad Holding Cayman Limited Dual atm and dna-pk inhibitors for use in anti-tumor therapy

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1827460A4 (en) 2004-12-09 2012-03-14 Univ Minnesota NUCLEOSIDE WITH ANTIVIRAL AND ANTI-CANCER EFFECT
JP5312320B2 (ja) 2006-06-01 2013-10-09 サノフイ プロテアーゼ阻害剤としてのスピロ環式ニトリル類
RU2478635C2 (ru) 2006-10-19 2013-04-10 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Гетероарильные соединения, содержащие их композиции и способы лечения с применением этих соединений
WO2009155527A2 (en) * 2008-06-19 2009-12-23 Progenics Pharmaceuticals, Inc. Phosphatidylinositol 3 kinase inhibitors
US8394818B2 (en) * 2008-10-17 2013-03-12 Dana-Farber Cancer Institute, Inc. Soluble mTOR complexes and modulators thereof
WO2010139747A1 (en) * 2009-06-04 2010-12-09 Novartis Ag 1H-IMIDAZO[4, 5-c]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES
WO2011071716A1 (en) 2009-12-07 2011-06-16 Boehringer Ingelheim International Gmbh Heterocyclic compounds containing an indole core
CN102399218A (zh) 2010-09-16 2012-04-04 和记黄埔医药（上海）有限公司 一类并合三杂环及其作为pi3k抑制剂的用途
RU2013130907A (ru) * 2010-12-06 2015-01-20 Пирамал Энтерпрайзис Лимитед Замещенные имидазохинолиновые производные
JO3003B1 (ar) 2011-01-14 2016-09-05 Lilly Co Eli مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor
AR089929A1 (es) 2012-02-10 2014-10-01 Actelion Pharmaceuticals Ltd Proceso para manufacturar un derivado de naftiridina
CN107652289B (zh) * 2012-06-13 2020-07-21 因塞特控股公司 作为fgfr抑制剂的取代的三环化合物
CN103936762B (zh) * 2013-01-17 2016-02-24 上海汇伦生命科技有限公司 吗啉并喹啉类化合物，其制备方法和用途
CN103880844A (zh) * 2014-04-09 2014-06-25 彭正中 一种喹啉酮类新化合物及其制备方法与用途
NO2714752T3 (es) * 2014-05-08 2018-04-21
CN105461712B (zh) * 2014-06-17 2019-01-29 上海嘉坦医药科技有限公司 作为mTOR/PI3K抑制剂的吡啶并[1,2-a]嘧啶酮类似物
CN105461711B (zh) * 2014-06-17 2018-11-06 正大天晴药业集团股份有限公司 作为PI3K抑制剂的吡啶并[1,2-a]嘧啶酮类似物
CA2952992C (en) * 2014-06-17 2019-05-07 Cisen Pharmaceutical Co., Ltd. Pyridino[1,2-a]pyrimidone analogue used as mtor/pi3k inhibitor
ES2754264T3 (es) * 2014-06-17 2020-04-16 Chia Tai Tianqing Pharmaceutical Group Co Ltd Análogo de piridin[1,2-a]pirimidona utilizado como inhibidor de PI3K
BR112017004704A2 (pt) 2014-09-17 2018-01-23 Verseon Corp composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio em um indivíduo
DK3560924T3 (da) 2015-04-02 2021-06-28 Merck Patent Gmbh Imidazolonylquinoliner og deres anvendelse som atm-kinase-inhibitorer
WO2016186453A1 (en) * 2015-05-20 2016-11-24 Kainos Medicine, Inc. Quinoline derivatives as bromodomain inhibitors
GB201519406D0 (en) * 2015-11-03 2015-12-16 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
GB201519568D0 (en) * 2015-11-05 2015-12-23 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
ES2904557T3 (es) 2016-01-20 2022-04-05 Biogen Ma Inc Agentes inhibidores de irak4
WO2017162611A1 (en) * 2016-03-21 2017-09-28 Astrazeneca Ab Quinoline-3-carboxamide compounds and their use in treating cancer
AR108222A1 (es) 2016-05-05 2018-08-01 Elanco Tiergesundheit Ag Compuestos heteroaril-1,2,4-triazol y heteroaril-tetrazol
GB201608227D0 (en) * 2016-05-11 2016-06-22 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
JP6997358B2 (ja) * 2018-09-30 2022-01-17 メッドシャイン ディスカバリー インコーポレイテッド キノリノピロリジン－２－オン系誘導化合物及びその使用
EP4003345B1 (en) 2019-07-30 2024-12-04 XRad Therapeutics, Inc. Dual atm and dna-pk inhibitors for use in anti-tumor therapy

Also Published As

Publication number Publication date
MA52364A (fr) 2021-03-03
EP3784671A4 (en) 2021-11-17
KR20210027251A (ko) 2021-03-10
EP4327877A3 (en) 2024-04-24
EP4327877A2 (en) 2024-02-28
AU2019254980A1 (en) 2020-12-03
JP7366996B2 (ja) 2023-10-23
CA3096732A1 (en) 2019-10-24
JP2021522316A (ja) 2021-08-30
US20220315606A1 (en) 2022-10-06
US12187742B2 (en) 2025-01-07
EP3784671B1 (en) 2023-10-11
EP3784671A1 (en) 2021-03-03
CN112469720A (zh) 2021-03-09
CN110386932A (zh) 2019-10-29
CN112469720B (zh) 2024-03-29
SG11202010212RA (en) 2020-11-27
BR112020021323A2 (pt) 2021-01-19

Similar Documents

Publication Publication Date Title
PH12020551717A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
MX2020010942A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
PH12020551305A1 (en) Pharmaceutical Compounds
PH12019502245A1 (en) Compounds that inhibit mcl-1 protein
PH12020552004A1 (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
CL2022000271A1 (es) Inhibidores de la fosfatasa shp2 de pirazolo(3,4-b)pirazina.
EA202091491A1 (ru) Новые бензиламинозамещенные пиридопиримидиноны и производные в качестве ингибиторов sos1
NZ775660A (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
PH12019550140A1 (en) Piperidine-substituted mnk inhibitors and methods related thereto
MX389597B (es) Inhibidores de cdk2/4/6 de piridopirimidinona.
PH12017500367A1 (en) Compounds that inhibit mcl-1 protein
PH12016501338A1 (en) Indazole compounds as irak4 inhibitors
MD20170016A2 (ro) Compuşi aminopirimidinici ca inhibitori JAK
MX2020001717A (es) Inhibidores macrociclicos de mcl-1 y metodos de uso.
PH12019501896A1 (en) Therapeutic dendrimers
GEAP202415883A (en) Macrocyclic compounds as sting agonists and methods and uses thereof
SA519402103B1 (ar) 1,6-naphthyridine مشتقات 1، 6 نفثيرايدين CDK4/6 على شكل مثبط
PH12019500569A1 (en) Blood-brain barrier-penetrant dopamine-b-hydroxylase inhibitors
PH12020500542A1 (en) Dopamine-b-hydroxylase inhibitors
MX2019004822A (es) Derivado del pirazol 3,4-bipiridilo y metodo de preparacion del mismo y aplicacion medica del mismo.
PH12021550323A1 (en) Dendrimer formulations
ZA202311007B (en) Organotrisulfide and organotetrasulfide compounds and the use thereof in methods of treatment
EA201992303A1 (ru) СОЕДИНЕНИЯ, КОТОРЫЕ ИНГИБИРУЮТ БЕЛОК Mcl-1